Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Mark T. Iwicki | Chief Executive Officer | -- | -- | 1966 |
| Dr. Christopher H. Cabell FACC, M.D. | President, Head of Research & Development and Chief Medical Officer | -- | -- | 1970 |
| Mr. Garth Lees-Rolfe CPA | Chief Financial Officer | -- | -- | 1985 |
| Dr. John Adams Ph.D. | Chief Scientific Officer | -- | -- | -- |
| Mr. Jeffrey J. Kagy | Chief Human Resources Officer | -- | -- | -- |
| Mr. Chadwick J. Orevillo MPH | Executive VP & Head of Development Operations | -- | -- | -- |
Inhibikase Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 15
Description
Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
Corporate Governance
Upcoming Events
May 13, 2025 at 8:00 PM UTC - May 19, 2025 at 8:00 PM UTC
Inhibikase Therapeutics, Inc. Earnings Date
Recent Events
December 3, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission